ENDRA regains Nasdaq stockholders' equity compliance, faces one-year panel monitor
ENDRA Life Sciences received a Nasdaq notice on July 8, 2026 that it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, after the Staff flagged a shortfall in its 2025 annual report. The company will be under a Discretionary Panel Monitor for one year from July 1, 2026, and if it falls out of compliance again within that period, it could face delisting without a cure period.
Key points
- Nasdaq Staff letter dated April 20, 2026 cited stockholders' equity below the $2,500,000 minimum, based on the 2025 Form 10-K
- Company requested a Nasdaq Hearing Panel hearing on April 27, 2026; hearing held May 28, 2026
- On July 8, 2026 Nasdaq notified the company it regained compliance
- One-year Discretionary Panel Monitor runs from July 1, 2026; a new deficiency could lead to a Delist Determination Letter and possible delisting
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.